IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin‐1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis
- 2 April 2018
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 70 (8) , 1319-1330
Abstract
Objective: To determine whether systemic juvenile idiopathic arthritis (JIA) susceptibility loci that were identified by candidate gene studies demonstrate association with systemic JIA in the largest study population assembled to date.Methods: Single‐nucleotide polymorphisms (SNPs) from 11 previously reported systemic JIA risk loci were examined for association in 9 populations, including 770 patients with systemic JIA and 6,947 controls. The effect of systemic JIA–associated SNPs on gene expression was evaluated in silico in paired whole genome and RNA sequencing data from the lymphoblastoid cell lines (LCLs) of 373 European subjects from the 1000 Genomes Project. Responses of systemic JIA–associated SNPs to anakinra treatment were evaluated in 38 US patients for whom treatment response data were available.Results: We found no association between the previously reported 26 SNPs and systemic JIA. Expanded analysis of the regions containing the 26 SNPs revealed only 1 significant association: the promoter region of IL1RN (P < 1 × 10–4). Systemic JIA–associated SNPs correlated with IL1RN expression in LCLs, with an inverse correlation between systemic JIA risk and IL1RN expression. The presence of homozygous IL1RN high expression alleles correlated strongly with a lack of response to anakinra therapy (odds ratio 28.7 [95% confidence interval 3.2–255.8]).Conclusion: In our study, IL1RN was the only candidate locus associated with systemic JIA. The implicated SNPs are among the strongest known determinants of IL1RN and interleukin‐1 receptor antagonist levels, linking low expression with increased systemic JIA risk. Homozygous high expression alleles predicted nonresponsiveness to anakinra therapy, making them ideal candidate biomarkers to guide systemic JIA treatment. This study is an important first step toward the personalized treatment of systemic JIA.Keywords
Funding Information
- National Human Genome Research Institute (Z01‐HG200370, Z99 HG999999, Z01‐HG‐200370)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01‐AR059049, R01‐AR060893, R01‐AR061297, Z01‐AR041198, Z99 AR999999, Z01‐AR‐041198)
- Bundesministerium für Forschung, Technologie und Raumfahrt (project 01ER0812, project 01ER0813, project 01ER0828)
- Arthritis Research UK (20385)
- National Institutes of Health (R01‐AR‐059049)
This publication has 37 references indexed in Scilit:
- Systemic-onset juvenile idiopathic arthritisAutoimmunity Reviews, 2016
- The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013The Journal of Rheumatology, 2016
- Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?Arthritis & Rheumatology, 2014
- Treatment advances in systemic juvenile idiopathic arthritisF1000Prime Reports, 2014
- Autoinflammatory gene polymorphisms and susceptibility to UK juvenile idiopathic arthritisPediatric Rheumatology, 2013
- Association of the IL-10 Gene Family Locus on Chromosome 1 with Juvenile Idiopathic Arthritis (JIA)PLOS ONE, 2012
- Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questionsNature Reviews Rheumatology, 2011
- Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritisGenes & Immunity, 2008
- Novel IL10 gene family associations with systemic juvenile idiopathic arthritisArthritis Research & Therapy, 2006
- Systemic juvenile idiopathic arthritis: diagnosis, management, and outcomeNature Clinical Practice Rheumatology, 2006